Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT02935036 Completed - Acne Vulgaris Clinical Trials

Efficacy Study in Patients With Acne Vulgaris.

Start date: October 3, 2016
Phase: Phase 2
Study type: Interventional

Safety and efficacy study in patients with acne vulgaris

NCT ID: NCT02932306 Completed - Acne Clinical Trials

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Start date: November 3, 2015
Phase: Phase 3
Study type: Interventional

The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score [EGSS] of 3 [moderate] or 4 [severe]).

NCT ID: NCT02932267 Completed - Acne Vulgaris Clinical Trials

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

EDeN
Start date: February 2, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with moderate to severe acne vulgaris on the face. All eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump Forte) once daily on whole face. The purpose of this trial is to evaluate subject reported outcomes with the combination of Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of moderate to severe acne in dark skin phototypes (IV to VI).

NCT ID: NCT02929719 Completed - Acne Vulgaris Clinical Trials

Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Start date: April 2014
Phase: Phase 1
Study type: Interventional

Therapeutic equivalence and safety study

NCT ID: NCT02924428 Terminated - Acne Vulgaris Clinical Trials

Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris

Start date: September 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the efficacy of facial acne vulgaris treatment using the Venus Versa Diamondpolar applicator in combination with the Venus Versa AC dual applicator using two intense pulsed light wavelength bands.

NCT ID: NCT02913001 Completed - Acne Vulgaris Clinical Trials

The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne

Start date: September 2014
Phase: N/A
Study type: Interventional

This randomized controlled trial will examine changes in some hormonal markers associated with acne among adults with moderate/severe acne randomized to a low glycemic index and glycemic load diet or usual eating plan for two weeks.

NCT ID: NCT02905851 Completed - Acne Vulgaris Clinical Trials

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris

Start date: May 2016
Phase: N/A
Study type: Interventional

To see if teledermatology can be used to reduce antibiotic burden in patients on doxycycline or minocycline for acne vulgaris

NCT ID: NCT02899000 Completed - Acne Vulgaris Clinical Trials

A Treatment for Severe Inflammatory Acne Subjects

Start date: July 29, 2016
Phase: Phase 4
Study type: Interventional

Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.

NCT ID: NCT02886715 Completed - Acne Vulgaris Clinical Trials

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Start date: September 21, 2016
Phase: Phase 3
Study type: Interventional

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

NCT ID: NCT02865005 Completed - Acne Vulgaris Clinical Trials

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

Start date: February 2016
Phase: Phase 3
Study type: Interventional

Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.